[go: up one dir, main page]

AU3696897A - Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis - Google Patents

Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis

Info

Publication number
AU3696897A
AU3696897A AU36968/97A AU3696897A AU3696897A AU 3696897 A AU3696897 A AU 3696897A AU 36968/97 A AU36968/97 A AU 36968/97A AU 3696897 A AU3696897 A AU 3696897A AU 3696897 A AU3696897 A AU 3696897A
Authority
AU
Australia
Prior art keywords
heterocyclic compounds
thrombolytic activity
treating thrombosis
thrombosis
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36968/97A
Inventor
Francoise Casadebaig
Jean-Pierre Dupin
Denis Gravier
Richard Gryglewsky
Genevieve Hou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU3696897A publication Critical patent/AU3696897A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU36968/97A 1996-07-12 1997-07-11 Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis Abandoned AU3696897A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9608969 1996-07-12
FR9608969A FR2750862B1 (en) 1996-07-12 1996-07-12 USE OF FUSED DIAZOTA HETEROCYCLES WITH AN AROMATIC OR HETEROAROMATIC SYSTEM FOR THE TREATMENT OF THROMBO-EMBOLIC DISEASES
PCT/FR1997/001278 WO1998002162A1 (en) 1996-07-12 1997-07-11 Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis

Publications (1)

Publication Number Publication Date
AU3696897A true AU3696897A (en) 1998-02-09

Family

ID=9494163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36968/97A Abandoned AU3696897A (en) 1996-07-12 1997-07-11 Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis

Country Status (7)

Country Link
EP (1) EP0912180A1 (en)
JP (1) JP2000514447A (en)
CN (1) CN1228701A (en)
AU (1) AU3696897A (en)
CA (1) CA2260965A1 (en)
FR (1) FR2750862B1 (en)
WO (1) WO1998002162A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702001D0 (en) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
US6469014B1 (en) 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
JP2002533465A (en) * 1998-12-23 2002-10-08 デュポン ファーマシューティカルズ カンパニー Heterobicycles containing nitrogen as factor Xa inhibitors
CA2398446A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
WO2002076946A2 (en) 2001-03-26 2002-10-03 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
CN100500679C (en) * 2001-11-01 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 Compound for adjusting functional activity of vascular endothelial cell, its preparation method as well as usage
CN100486981C (en) * 2001-11-02 2009-05-13 中国人民解放军军事医学科学院毒物药物研究所 Compound possessing function for preventing and curing atherosclerosis and its application in biologic pharmacological science
CN100486982C (en) * 2001-11-02 2009-05-13 中国人民解放军军事医学科学院毒物药物研究所 Compound possessing function for preventing and curing thrombus disease, its pharmacy composition and usage in medication
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AU2009252938B2 (en) 2008-05-27 2012-04-26 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
US20120122889A1 (en) * 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
EA201690713A1 (en) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
AR103297A1 (en) 2014-12-30 2017-05-03 Forma Therapeutics Inc PIRROLO AND PIRAZOLOPIRIMIDINAS AS INHIBITORS OF THE SPECIFIC PROTEASE 7 OF UBIQUITINA
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
HK1248221A1 (en) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
CN114230571B (en) 2015-09-14 2025-07-08 无限药品股份有限公司 Solid forms of isoquinolinones, methods of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2019243186A1 (en) 2018-03-30 2020-10-15 Biotheryx, Inc. Thienopyrimidinone compounds
JPWO2021054393A1 (en) * 2019-09-19 2021-03-25

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02169520A (en) * 1988-12-22 1990-06-29 Tsumura & Co Microcirculation improving agent
JP2657760B2 (en) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4-aminoquinazoline derivatives and pharmaceuticals containing them
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
FR2750862B1 (en) 1998-10-16
CA2260965A1 (en) 1998-01-22
CN1228701A (en) 1999-09-15
FR2750862A1 (en) 1998-01-16
WO1998002162A1 (en) 1998-01-22
JP2000514447A (en) 2000-10-31
EP0912180A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AU3696897A (en) Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis
HU9702034D0 (en) Heterocyclic compounds of leukocita-adhesion-inhibitor and vla-4-antagonist activity
ZA977901B (en) Heterocyclic esters and amides.
HUP0004170A3 (en) Methods and materials for treating and preventing inflammation ofmucosal tissue
PL331795A1 (en) Heterocyclic metaloprotease inhibitors
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
AU4009795A (en) Heterocyclic compounds and their use
HU9702036D0 (en) New heterocyclic compounds as inhibitors of leucocita-adhesion and wla-4-antagonists
ZA939416B (en) Modified lipolytic enzymes and their use
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
PL331465A1 (en) Novel compounds and agents for treating diseases associated with triptase activity
HUP0100353A3 (en) Naphtamidine derivatives with urokinase inhibitor activity
HUP9702242A3 (en) Inozitol-glykanes of inzulin-like activity
ZA939415B (en) Modified lipolytic enzymes and their use
HUP9700660A3 (en) Use of alpha-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating hyperplasia benigna prostatae
GB9425701D0 (en) Enzyme inhibitors
AU1766997A (en) Beta-thiopropionyl-aminoacid derivatives and their use as beta-lactamase inhibitors
NZ325587A (en) 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity
SI0922703T1 (en) Substituted heterocyclic benzocycloalkenes and their use as analgesically active compounds
AU1081897A (en) Heterocyclic compounds and their use
ZA9714B (en) Bioregulatory active substance method for its production and use thereof
GB9623539D0 (en) Enzymes and their use
AU1439497A (en) Substituted n-aryl nitrogen heterocyclic compounds and their use as herbicides
GB9616563D0 (en) Compounds and methods
AP9801430A0 (en) Anticonvulsant derivatives useful on treating psoriasis

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted